Cat. No.: HY-14444

Plinabulin

(Synonyms: NPI-2358)

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Plinabulin (NPI-2358) is a vascular disrupting agen (VDA) against tubulin-depolymerizing with an IC₅₀ of 9.8 nM against HT-29 cells. Plinabulin binds the colchicine binding site of β-tubulin preventing polymerization and has potent inhibitory to tumor cells.

For research use only. We do not sell to patients.

Purity: 98.0%
CAS No.: 714272-27-2
Formula: C₁₉H₂₀N₄O₂
Molecular Weight:336.39

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Plinabulin Chemical Structure

CAS No.: 714272-27-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Plinabulin (NPI-2358) is a vascular disrupting agen (VDA) against tubulin-depolymerizing with an IC₅₀ of 9.8 nM against HT-29 cells^[1]. Plinabulin binds the colchicine binding site of β-tubulin preventing polymerization and has potent inhibitory to tumor cells^[2].

IC₅₀ & Target

β-tubulin^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.0055 μM Compound: NPI-2358	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 27318124]
A549	IC₅₀	0.01 μM Compound: Plinabulin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
A549	IC₅₀	3.5 nM Compound: Plinabulin	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30910474]
A549	IC₅₀	35.7 nM Compound: 1	Cytotoxicity against human A549 cells after 48 hrs by WST8 assay Cytotoxicity against human A549 cells after 48 hrs by WST8 assay	[PMID: 25313318]
BGC-823	IC₅₀	0.009 μM Compound: Plinabulin	Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
BXPC-3	IC₅₀	18.4 nM Compound: Plinabulin	Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition by MTT assay	[PMID: 37301522]
BXPC-3	IC₅₀	4.28 nM Compound: Plinabulin	Antiproliferative activity against human BxPC3 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human BxPC3 cells after 72 hrs by sulforhodamine B assay	[PMID: 29571653]
BXPC-3	IC₅₀	5.8 nM Compound: Plinabulin	Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32278711]
DU-145	IC₅₀	0.014 μM Compound: NPI-2358	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 27318124]
HCT-116	IC₅₀	6 nM Compound: Plinabulin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 31759826]
HCT-116	IC₅₀	8.8 nM Compound: Plinabulin	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition by MTT assay	[PMID: 37301522]
HeLa	IC₅₀	0.0084 μM Compound: NPI-2358	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 27318124]
HeLa	IC₅₀	0.01 μM Compound: Plinabulin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
HeLa	IC₅₀	20.6 nM Compound: 1	Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay	[PMID: 25313318]
HeLa	IC₅₀	9 nM Compound: Plinabulin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 31759826]
HepG2	IC₅₀	4.8 nM Compound: Plinabulin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 31759826]
HL-60	IC₅₀	0.01 μM Compound: Plinabulin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
HL-60	IC₅₀	0.0148 μM Compound: NPI-2358	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 27318124]
HT-29	IC₅₀	0.013 μM Compound: NPI-2358	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 27318124]
HT-29	IC₅₀	13.5 nM Compound: 1, NPI-2358, KPU-2	Cytotoxicity against human HT-29 cells after 72 hrs by XTT/PMS method Cytotoxicity against human HT-29 cells after 72 hrs by XTT/PMS method	[PMID: 21106379]
HT-29	IC₅₀	14.9 nM Compound: 11, KPU-2/NPI-2358, Plinabulin	Cytotoxicity against human HT-29 cells after 48 hrs using resazurin by microplate fluorometer analysis Cytotoxicity against human HT-29 cells after 48 hrs using resazurin by microplate fluorometer analysis	[PMID: 22185476]
HT-29	IC₅₀	15 nM Compound: 3, NPI-2358/KPU-2	Cytotoxicity against human HT-29 cells after 48 hrs by resazurin assay Cytotoxicity against human HT-29 cells after 48 hrs by resazurin assay	[PMID: 22727370]
HT-29	IC₅₀	15 nM Compound: 1, NPI-2358/KPU-2	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 20395148]
HT-29	IC₅₀	18 nM Compound: NPI-2358	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 21835627]
HT-29	IC₅₀	6.6 nM Compound: Plinabulin	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32278711]
Huh-7	IC₅₀	0.031 μM Compound: Plinabulin	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
HUVEC	IC₅₀	10 nM Compound: Plinabulin	Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth	[PMID: 30542530]
HUVEC	IC₅₀	11 nM Compound: 11, KPU-2/NPI-2358, Plinabulin	Cytotoxicity against HUVEC after 48 hrs using resazurin by microplate fluorometer analysis Cytotoxicity against HUVEC after 48 hrs using resazurin by microplate fluorometer analysis	[PMID: 22185476]
Jurkat	IC₅₀	3.3 nM Compound: Plinabulin	Cytotoxicity against human Jurkat cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28228362]
K562	IC₅₀	0.0063 μM Compound: NPI-2358	Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 27318124]
K562	IC₅₀	0.008 μM Compound: Plinabulin	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
MCF7	IC₅₀	0.01 μM Compound: Plinabulin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
MCF7	IC₅₀	0.0126 μM Compound: NPI-2358	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 27318124]
MCF7	IC₅₀	29.8 nM Compound: Plinabulin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 31759826]
NCI-H1975	IC₅₀	0.011 μM Compound: Plinabulin	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
NCI-H1975	IC₅₀	10.2 nM Compound: Plinabulin	Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30910474]
NCI-H446	IC₅₀	44.2 nM Compound: Plinabulin	Cytotoxicity against human NCI-H446 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H446 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28228362]
NCI-H460	IC₅₀	26.2 nM Compound: Plinabulin	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 31759826]
NCI-H460	IC₅₀	26.2 nM Compound: Plinabulin	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32278711]
NCI-H460	IC₅₀	30.9 nM Compound: Plinabulin	Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition by MTT assay	[PMID: 37301522]
NCI-H460	IC₅₀	33.9 nM Compound: Plinabulin	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28228362]
U-937	IC₅₀	0.006 μM Compound: Plinabulin	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
U-937	IC₅₀	0.0068 μM Compound: NPI-2358	Cytotoxicity against human U-937 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human U-937 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 27318124]

In Vitro

Plinabulin (NPI-2358) (2-200 nM; 30 minutes; HUVECs cells) is a potent anti-tumor agent which is active in multidrug-resistant (MDR) tumor cell lines, and is able to rapidly induce tubulin depolymerization and monolayer permeability in HUVECs, with IC₅₀ values of 18 nM for DU 145 cells; 13 nM for PC-3 cells; 14 nM for MDA-MB-231 cells; 18 nM for NCI-H292 cells; and 11 nM for Jurkat leukemia cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HUVECs cells
Concentration:

2 nM, 10 nM, 20 nM and 200 nM
Incubation Time:

30 minutes
Result:

Low concentrations (2 nM, 10 nM) rapidly induced tubulin depolymerization in HUVECs.

In Vivo

Plinabulin (0 mg/kg-15 mg/kg; intraperitoneal injection; female CDF1 and C3H/He mice) induces a time- and dose-dependent decrease in tumor perfusion. The KHT sarcoma is more sensitive than the C3H tumor to the anti-tumor effects of Plinabulin, while radiation response is enhanced in both models^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female CDF1 mice (10-14-week-old) with C3H mammary carcinoma; Female C3H/HeJ mice with KHT sarcoma cells (8-weeks-old)^[3]
Dosage:

0 mg/kg, 1.5 mg/kg, 2.5 mg/kg, 5 mg/kg, 7.5 mg/kg, 10 mg/kg, 12.5 mg/kg, 15 mg/kg;
0.02 mL/g mouse body weight in CDF1 mice and 0.01 mL/g body weight for C3H/HeJ mice
Administration:

Intraperitoneal injection; 0 huor, 1 huor, 3 hours, 6 huors, 24 huors
Result:

Induced a time- and dose-dependent decrease in tumour perfusion. The KHT sarcoma was more sensitive than the C3H tumour to the anti-tumor, while radiation response was enhanced in both models.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 714272-27-2
Appearance Solid
Molecular Weight 336.39
Formula C₁₉H₂₀N₄O₂
Color Light yellow to yellow
SMILES

O=C(N/C1=C\C2=C(NC=N2)C(C)(C)C)/C(NC1=O)=C/C3=CC=CC=C3
Synonyms

NPI-2358
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All

Sort by:

Journal Impact Factor

Clin Transl Med

Mechanism of Gzma-mediated GEF-H1 activation in intestinal epithelial cells leading to intestinal barrier dysfunction in sepsis. [Abstract]

2026 Apr;16(4):e70651. PMID: 41943423
Patent

US20250161243A1.
bioRxiv

Diverse microtubule-destabilizing drugs induce equivalent molecular pathway responses in endothelial cells. [Abstract]

2025 Jan 24:2025.01.22.632572. PMID: 39896568

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (148.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9727 mL

14.8637 mL

29.7274 mL

5 mM

0.5945 mL

2.9727 mL

5.9455 mL

10 mM

0.2973 mL

1.4864 mL

2.9727 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (7.43 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Nicholson B et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31. [Content Brief]

[2]. Monica M. Mita et al. Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas Clin Cancer Res. 2010 Dec 1;16(23):5892-9. [Content Brief]

[3]. Bertelsen LB, et al. Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. Int J Radiat Biol. 2011 Nov;87(11):1126-34. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9727 mL	14.8637 mL	29.7274 mL	74.3185 mL
	5 mM	0.5945 mL	2.9727 mL	5.9455 mL	14.8637 mL
	10 mM	0.2973 mL	1.4864 mL	2.9727 mL	7.4318 mL
	15 mM	0.1982 mL	0.9909 mL	1.9818 mL	4.9546 mL
	20 mM	0.1486 mL	0.7432 mL	1.4864 mL	3.7159 mL
	25 mM	0.1189 mL	0.5945 mL	1.1891 mL	2.9727 mL
	30 mM	0.0991 mL	0.4955 mL	0.9909 mL	2.4773 mL
	40 mM	0.0743 mL	0.3716 mL	0.7432 mL	1.8580 mL
	50 mM	0.0595 mL	0.2973 mL	0.5945 mL	1.4864 mL
	60 mM	0.0495 mL	0.2477 mL	0.4955 mL	1.2386 mL
	80 mM	0.0372 mL	0.1858 mL	0.3716 mL	0.9290 mL
	100 mM	0.0297 mL	0.1486 mL	0.2973 mL	0.7432 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Plinabulin

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Cytoskeleton Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Rare Diseases Drug Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Plinabulin

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Plinabulin

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Cytoskeleton Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Rare Diseases Drug Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Plinabulin

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Plinabulin Related Classifications

HY-14444 Related Classifications